Scale from Small-Batch Lab to Multi-Kilo GMP
With the completion of phase 1 we can develop late-phase formulations in our R&D lab, but what if you need to quickly scale to GMP manufacturing?
At J-STAR Research, we have the ability to quickly forward your formulation to our parent company (Porton Pharma Solutions Ltd.) for large-scale, multi-kilo GMP, but if you prefer stay local, we also have many national partners with robust commercial capacity we collaborate with on a regular basis.
Provide Phase Appropriate Formulation through Decision Tree and Target Product Profile
Whether it is Phase 1 or 2 or 3 formulation design, we are guided by formulation decisions based on fundamental material properties, supported by appropriate use of Quality Target Product Profile (QTPP) tailored for the appropriate clinical phase.
Phase Appropriate QbD Based Formulation Development
We understand the requirements of each phase of development. While timeline and maximum exposure are important in Phase 1, scale up and appropriate process design are increasingly emphasized as we move forward to Phases 2 and 3.
Formulation and formulation process design are based on risk assessment appropriate DS material properties that are the Critical Quality Attributes.
J-Star Research experienced specialists can compile high-quality drug product development report for CMC section in support of regulatory flings (IND, NDA, and/or ANDA); and can provide documents in the desired format to facilitate any response to CMC questions raised for the global regulatory applications.
Trouble Shooting - Formulation
Using Advanced tools to investigate problems related to formulations including but not limited to:
Trouble Shooting - Process
Connect With Us
J-STAR Research helps pharmaceutical small molecule R&D programs succeed in all phases of development.